Corporate Update – Tianjin Pharmaceutical Da
During the most recent 24‑hour trading window, which closed at 03:34 PM Central European Time on Thursday, 22 October 2026, the shares of Tianjin Pharmaceutical Da (ticker T14.SI) experienced a modest uptick, rising 0.38 % to a closing price of approximately USD 2.60 on the Singapore Exchange.
Trading Snapshot
| Metric | Value |
|---|---|
| Current price | USD 2.60 |
| Market cap | USD 3.30 bn |
| Total shares outstanding | 200 million |
| 24‑h trading volume | USD 550.8 k |
| 12‑month high | USD 3.75 (23 Feb 2026) |
| 12‑month low | USD 2.45 (11 Sep 2026) |
| 200‑day moving average | USD 3.00 |
| Year‑to‑date gain | 6.37 % |
The stock’s modest rise comes against a backdrop of relative stability in its sector, with peer companies showing a mixed performance.
Peer Performance Overview
| Company | Ticker | 24‑h Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Everbright Securities L‑H | 6178.HK | –0.6 % | HKD 6.53 | HKD 31.2 bn | 6.8 |
| Beijing Sifang Automation | 601126.SS | 0 % | CNY 30.58 | CNY 26.1 bn | 30.45 |
| Zhejiang Weiming Environme | 603568.SS | 0 % | CNY 12.64 | CNY 26.2 bn | 16.34 |
| Shenzhen Fortune Trend Tec | 688318.SS | 0 % | CNY 72.35 | CNY 26.1 bn | 88.77 |
| MGI Tech | 688114.SS | 0 % | CNY 63.27 | CNY 26.2 bn | – |
Everbright Securities L‑H, the only peer to exhibit a negative movement in the same period, still retains a healthy market cap and a low price‑to‑earnings ratio, signalling resilience in a volatile market environment. The other peers traded flat, reflecting a broader market equilibrium.
Company Profile
Tianjin Pharmaceutical Da Re Tang Group Corp. Ltd., incorporated in 1992 and listed on the Singapore Exchange since 27 June 1997, is a diversified healthcare entity headquartered in Tianjin, China. Its operations span:
- Production and sale of traditional Chinese medicines, western pharmaceuticals, and health‑care products within the People’s Republic of China.
- Manufacturing and distribution of biopharmaceuticals, biochemical products, and daily‑use items.
- Hospital operations, including wholesale and retail medicine sales.
- Ancillary services such as logistics, inventory management, equipment installation, and medicine processing.
The company markets its products under its own brand as well as other licensed brands to wholesalers. Strategic partnerships, notably with Ping An Good Doctor, enhance its reach in digital health services.
The firm’s website, www.zhongxinyaoye.com , offers detailed information on its product lines, corporate governance, and sustainability initiatives.
Market Context
The modest gain in Tianjin Pharmaceutical Da’s share price reflects a cautiously optimistic sentiment among investors, who are closely watching the company’s expansion into digital health services and its potential to capture market share in both traditional and modern pharmaceutical segments. The 200‑day moving average at USD 3.00 suggests that the stock is still trading slightly below its medium‑term trend, leaving room for potential upside should the company continue to execute on its growth strategies.
In summary, Tianjin Pharmaceutical Da remains a solid, albeit modestly appreciating, holding in the pharmaceutical sector, supported by a diversified product portfolio and strategic digital partnerships. Its performance relative to peers indicates a resilient position amid a broadly balanced market landscape.
